Biometry Research Group

Curriculum Vitae for Grant Izmirlian, PhD
Mathematical Statistician

US Mail Address Biometry Research Group, DCP National Cancer Institute Executive Plaza North, Room 3131 6130 Executive Blvd, MSC 7354 Bethesda, MD 20892-7354	Shipping Address Biometry Research Group, DCP National Cancer Institute 6130 Executive Blvd, Room 3131 Rockville, MD 20852
Phone: (301) 496-7519  •  Fax: (301) 402-0816 E-mail: Izmirlian@nih.gov

---

• Professional Experience
• Education
• Awards and Honors
• Memberships
• Referee Services
• Editorial Board
• Research Interests
• Bibliography
  • Peer-Reviewed Journals
  • Published Abstracts

---

Professional Experience

08/1999-present	Mathematical Statistician Biometry Research Group, Division of Cancer Prevention National Cancer Institute, National Institutes of Health Bethesda, MD
02/1998-08/1999	Senior Staff Fellow Biometry Office, Epidemiology Demography & Biometry Program National Institute on Aging Bethesda, MD
06/1993-08/1993	Actuarial Research Intern Corporate Actuarial Department The Principal Financial Group; Des Moines, Iowa.
09/1992-05/1993	Visiting Assistant Professor Department of Mathematics and Computer Science Drake University, Des Moines, Iowa
09/1984-05/1990	Teaching Assistant Department of Mathematics University of Wisconsin-Madison
06/1996-08/1996	Graduate Research Fellow General Motors Technical Center, Warren, Michigan Department of Mathematics and Statistics

Back to top

Education

08/1996-02/1998	IRTA Fellowship Epidemiology, Demography, and Biometry Program National Institute on Aging, Bethesda, Maryland
08/1994-08/1996	Post-doctoral Training Fellowship in the Carolina Population Center and Biostatistics Department University of North Carolina – Chapel Hill
05/1993	PhD in Mathematics (Probability Theory) with a minor in Computer Science University of Wisconsin – Madison Thesis: Large deviations for additive functionals of a Markov exchangeable sequence. Advisor: Peter E. Ney, Professor of Mathematics
05/1984	BA in Mathematics and Chemistry Drake University Des Moines, Iowa

Back to top

Awards and Honors

2011	Prostate Cancer Foundation Award for Abstract Entitled "Family History of Various Cancers and the Risk of Incident Prostate Cancer in the PLCO Trial"
2010	Performance Award National Cancer Institute; Bethesda, Maryland
2002	Distinguished Service Award National Cancer Institute; Bethesda, Maryland
1999	Performance Award National Institute on Aging; Bethesda, Maryland
1998	Fellows Award for Research Excellence National Institutes of Health
1994	Carolina Population Center Fellowship University of North Carolina-Chapel Hill
1992	Department of Education Fellowship Department of Mathematics University of Wisconsin-Madison
1984	Member, Phi Beta Kappa
1984	Graduated summa cum laude Drake University; Des Moines, Iowa
1982 & 1983	Summer Landau Fellow in Physical Chemistry University of Minnesota-Minneaplolis

Back to top

Memberships

• American Statistical Association
• Eastern North American Region of the International Biometric Society
• Institute of Mathematical Statistics
• Interface Society of North America

Back to top

Referee Services

• Bioinformatics
• Biomed Central-Bioinformatics
• Journal of the American Statistical Association
• Nucleic Acids Research
• Proteomics
• Statistics in Medicine

Back to top

Editorial Boards

• Cancer Informatics

Back to top

Research Interests

1. Statistical analysis of proteomics, SNP and microarray data
2. Statistical issues related to interim analysis
3. Stochastic processes issues in natural history models for cancer screening trials

Back to top

Bibliography

Peer-Reviewed Journals

Andriole GL, Crawford ED, Grubb III RL, Buys SS, Chia C, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O’Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorok PC, and for the PLCO Project Team. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up . J Natl Cancer Inst 2012;104(2):125-132.

Berger VW, Izmirlian G, Knoll D. Discussion of the paper of Ghosh, Taylor, and Sargent . Biometrics 2012;68(1):239-241.

Schoen RE, Pinsky PF, Weissfeld L, Yokochi LA, Church T, Laiyemo AO, Bresalier R, Andriole GL, Buys SS, Crawford ED, Fouad MN, Isaacs C, Johnson CC, Reding DJ, O’Brien B, Carrick DM, Wright P, Riley TL, Purdue MP, Izmirlian G, Kramer BS, Miller AB, Gohagan JK, Prorok PC, Berg CD; the PLCO Project Team. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy . N Engl J Med 2012;366(25):2345-2357.

Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, Reding DJ, Greenlee RT, Yokochi LA, Kessel B, Crawford ED, Church TR, Andriole GL, Weissfeld JL, Fouad MN, Chia D, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hartge P, Pinsky PF, Zhu CS, Izmirlian G, Kramer BS, Miller AB, Xu J-L, Prorok PC, Gohagan JK, Berg CD for the PLCO Project Team. Effect of screening on ovarian cancer mortality. the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. JAMA 2011;305(22):2295-2303.

Oken MM, Hocking WG, Kvale PA, Andriole GL, Buys SS, Church TR, Crawford ED, Fouad MN, Isaacs C, Reding DJ, Weissfeld JL, Yokochi LA, O’Brien B, Ragard LR, Rathmell JM, Riley TL, Wright P, Caparaso N, Hu P, Izmirlian G, Pinsky PF, Prorok PC, Kramer BS, Miller AB, Gohagan JK, Berg CD, for the PLCO Project Team. Screening by chest radiograph and lung cancer mortality: The Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Trial . JAMA 2011;306(17):1865-1873.

The National Lung Cancer Screening Trial Research Team (Izmirlian G). Reduced lung-cancer mortality with low-dose computed tomograpic screening. N Engl J Med 2011;365(5):395-409.

The National Lung Screening Trial Research Team (Izmirlian G). The National Lung Screening Trial: overview and study design. Radiology 2011;258:243-253.

Crawford ED, Grubb RL, Black A, Andriole GL, Chen MH, Izmirlian G, Berg CD, D'Amico AV. Comorbidity and mortality results from a randomized prostate cancer screening trial . J Clin Oncol 2010;28.

Izmirlian G. Prostate-cancer screening. N Engl J Med 2009;361(2):204; author reply 205-206.

Andriole GL, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, Crawford ED, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1309-1319.

Grubb RL, Black A, Izmirlian G, Hickey TP, Pinsky PF, Mabie JE, Riley TL, Ragard LR, Prorok PC, Berg CD, Crawford ED, Church TR, Andriole GL. Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial. Cancer Epidemiology, Biomarkers and Prevention 2009;18(3):748-751.

Grubb RL, Pinsky PF, Greenlee RT, Izmirlian G, Miller AB, Hickey TP, Riley TL, Mabie JE, Levin DL, Chia D, Kramer BS, Reding DJ, Church TR, Yokochi LA, Kvale PA, Weissfeld JL, Urban DA, Buys SS, Gelmann EP, Ragard LR, Crawford ED, Prorok PC, Gohagan JK, Berg CD, Andriole GL. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int 2008;102(11):1524-1530.

Izmirlian G. Reply to 'Open Source Mathematical Software'. Notices of the American Mathematical Society 2008;55(3):342.

Izmirlian G. Response to 'Receiver operating characteristics of the prostate-specific antigen test in an unselected population'. J Med Screen 2006;13(4):214; author reply 215.

Steele VE, Arnold JT, Le H, Izmirlian G, Blackman MR. Comparative effects of DHEA and DHT on gene expression in human LNCaP prostate cancer cells. Anticancer Research 2006;26:3205-3216.

Xu J-L, Izmirlian G. Estimation of location parameters for a spherically symmetric distribution. Journal of Multivariate Analysis 2006;97:514-525.

Andriole GL, Levin DL, Crawford ED, Gelmann EP, Pinsky PF, Chia D, Kramer BS, Reding D, Church TR, Grubb RL, Izmirlian G, Ragard LR, Clapp JD, Prorok PC, Gohagan JK, for the PLCO Project Team. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 2005;97:433-438.

Baker SG,Izmirlian G, Kipnis V. Resolving paradoxes involving surrogate endpoints (pdf, 114kb). J R Statist Soc A 2005;168(4):753-762.

Buys SS, Partridge E, Greene MH, Prorok PC, Reding D, Riley TL, Hartge P, Fagerstrom RM, Ragard LR, Chia D, Izmirlian G, Fouad M, Johnson CC, Gohagan JK, for the PLCO Project Team. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 2005;193(5):1630-1639.

Cronin KA, Yu B, Krapcho M, Miglioretti DL, Fay MP,Izmirlian G, BallardBarbash R, Geller BM, Feuer EJ. Modeling the dissemination of mammography in the United States. Cancer Causes Control 2005;16(6):701-712.

Izmirlian G. Application of the random forest classification algorithm to a SELDITOF proteomics study in the setting of a cancer prevention trial. Ann NY Acad Sci 2004;1020:154-174.

Kapetanovic IM, Rosenfeld S, Izmirlian G. Overview of commonly used bioinformatics methods and their applications. Ann NY Acad Sci 2004;1020:10-21.

Xiao Z, Luke BT, Izmirlian G, Umar A, Lynch PM, Phillips RK, Patterson S, Conrads TP, Veenstra TD, Greenwald P, Hawk ET, Ali IU. Serum proteomic profiles suggest celecoxib-modulated targets and response predictors. Cancer Res 2004;64(8):2904-2909.

Melzer D, Izmirlian G, Leveille SG, Guralnik JM. Educational differences in the prevalence of mobility disability in old age: the dynamics of incidence, mortality, and recovery.J Gerontol B Psychol Sci Soc Sci 2001;56(5):S294-301.

Havlik RJ, Izmirlian G, Petrovitch H, Ross GW, Masaki K, Curb JD, Saunders AM, Foley DJ, Brock D, Launer LJ, White L. APOE-epsilon4 predicts incident AD in Japanese-American men: the Honolulu-Asia Aging Study. Neurology 2000;54(7):1526-1529.

Izmirlian G, Brock D, Ferrucci L, Phillips C. Active life expectancy from annual follow-up data with missing responses. Biometrics 2000;56(1):244-248.

Izmirlian G, Brock D, White L. Estimating incidence of dementia subtypes: assessing the impact of missed cases. Stat Med 2000;19(11-12):1577-1591

Leveille SG, Penninx BW, Melzer D, Izmirlian G, Guralnik JM. Sex differences in the prevalence of mobility disability in old age: the dynamics of incidence, recovery and mortality. J Gerontol B Psychol Sci Soc Sci 2000;55(1):S41-50.

Masaki KH, Losonczy KG, Izmirlian G, Foley DJ, Ross GW, Petrovitch H, Havlik R, White LR. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 2000;54(6):1265-1272.

Masaki KH, White LR, Foley DJ, Petrovitch H, Izmirlian G, Havlik R, Ross GW, Losonczy KG. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men - Reply.Neurology 2000;55(6):901-902.

Petrovitch H, White LR,Izmirlian G, Ross GW, Havlik RJ, Markesbery W, Nelson J, Davis DG, Hardman J, Foley DJ, Launer LJ. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Neurobiology of Aging 2000;21:57-62.

Corti MC, Guralnik JM, Ferrucci L, Izmirlian G, Leveille SG, Pahor M, Cohen HJ, Pieper C, Havlik RJ. Evidence for a black-white crossover in all-cause and coronary heart disease mortality in an older population: the North Carolina EPESE. Am J Public Health 1999;89(3):308-314.

Ferrucci L,Izmirlian G, Leveille S, Phillips CL, Corti MC, Brock DB, Guralnik JM. Smoking, physical activity, and active life expectancy. Am J Epidemiol 1999;149(7):645-653.

Foley DJ, Monjan AA,Izmirlian G, Hays JC, Blazer DG. Incidence and remission of insomnia among elderly adults in a biracial cohort. Sleep 1999;22:S373-378.

Rantanen T, Guralnick JM, Izmirlian G, Williamson JD, Simonsick EM, Ferrucci L, Fried LP. Association of muscle strength with maximum walking speed in disabled older women. Am J Phys Med Rehabil 1998;77(4):299-305.

Rantanen T, Guralnick JM, Leveille S, Izmirlian G, Hirsch R, Simonsick E, Ling S, Fried LP. Racial differences in muscle strength in disabled older women. J Gerontol A Biol Sci Med Sci 1998;53(5):B355-361.

Rantanen T, Masaki K, Foley D, Izmirlian G, White L, Guralnik JM. Grip strength changes over 27 yr in Japanese-American men. J Appl Physiol 1998;85(6):2047-2053.

Izmirlian G, Adewuyi AA, Suchindran CM. Analysis of contraceptive discontinuation in six developing countries from durations of use at survey. Soc Biol 1997;44(1-2):124-135.

Thompson TC, Izmirlian G, Lemon S, Truhlar DG, Mead CA. Consistent analytic representation of the two lowest potential energy surfaces for Li3, Na3, and K3. Journal of Chemical Physics 1985;82(12):5597-5603.

Back to top

Published Abstracts

Grubb RL, Black A, Church TR, Hickey T, Izmirlian G, Riley T, Prorok PC, Berg CD, Crawford ED, Andriole GL. Effect of obesity at age 20 and 50 on development of prostate cancer in the PLCO cancer screening trial. J Urol 2009;181(4):61-62.

Izmirlian G, Grubb RL, Black A, Prorok PC, Berg CD, Crawford ED, Andriole GL, Kibel AS. Pre-biopsy prostate cancer nomograms based upon serial PSA screening data in the PLCO trial with verification bias correction. J Urol 2009;181(4):609-609.

Black A, Grubb RL, Hickey T, Pinsky PF, Reding D, Izmirlian G, Mabie J, Riley T, Ragard LR, Prorok PC, Berg CD, Crawford ED, Andriole GL. Initial PSA levels and prostate cnancer diagnosis with up to 7 years follow-up in the PLCO cancer screening trial. J Urol 2009;181(4):647-647.

Black A, Grubb RL, Pinsky PF, Hickey T, Riley T, Izmirlian G, Ragard LR, Berg CD, Prorok PC, Crawford ED, Andriole GL. Factors influencing method of investigation of an abnormal PSA in the PLCO trial and effect on cancer diagnosis. J Urol 2009;181(4):799-800.

Grubb RL, Black A, Reding D, Hickey T, Pinsky PF, Church TR, Izmirlian G, Riley T, Mabie J, Ragard LR, Berg CD, Prorok PC, Crawford ED, Andriole GL. Pattern of PSA change during serial screening in the PLCO cancer screening trial affects prostate cancer risk. J Urol 2009;181(4):811-812.

Grubb RL, Black A, Church TR, Hickey T, Izmirlian G, Pinsky P, Mabie J, Riley TL, Ragard L, Prorok PC, Berg CD, Crawford ED, Andriole GL. Does BMI impact PSA concentration by variation in plasma volume? J Urol 2008;179(4):703-704.

Grubb RL, Pinsky P, Levin D, Hickey T, Mabie J, Riley TL, Izmirlian G, Ragard L, Crawford ED, Andriole GL. Outcomes of men with initial elevated PSA over three subsequent annual screening rounds in PLCO. J Urol 2007;177(4):626-626.

Tooze JA,Izmirlian G, Brown C, Perkins S, Hursting S. Armitage-Doll analysis of diet: p53 gene dosage interactions in p53-deficient and wild-type mice. FASEB J 2003;17:A1153.

Wang T, Izmirlian G, Takahashi Y, Perkins S, Hursting S. Microarray expression profiling of LNCaP prostate cancer cell gene expression following exposure to the soy isoflavone genistein. FASEB J 2003:17:A1372.

Kipnis V,Izmirlian G. The impact of categorization of continuous exposure measured with error. Am J Epidemiol 2002:155(11):S28 (Abstract 111).

Kipnis V, Izmirlian G, Midthune D, Subar A, Schatzkin A. Misclassification of dietary exposure and its implications: results from the Observing Protein and Energy Nutrition (OPEN) Biomarker Study. Am J Epidemiol 2002:155(11):S28 (Abstract 110).

Back to top

This page was last updated July 11, 2012.